Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 4315129)

Published in Cancer Growth Metastasis on January 29, 2015

Authors

Kimberly M Arnold1, Lynn M Opdenaker2, Daniel Flynn1, Jennifer Sims-Mourtada1

Author Affiliations

1: Center for Translational Cancer Research, Helen F. Graham Cancer Center, Christiana Care Health Services, Inc., Newark, DE, USA. ; Department of Medical Laboratory Sciences, University of Delaware, Newark, DE, USA.
2: Center for Translational Cancer Research, Helen F. Graham Cancer Center, Christiana Care Health Services, Inc., Newark, DE, USA. ; Department of Biological Sciences, University of Delaware, Newark, DE, USA.

Associated clinical trials:

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer | NCT01130142

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | NCT01088815

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | NCT01064622

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma | NCT00833417

Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | NCT01195415

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01098344

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | NCT00636610

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) | NCT00106145

Resveratrol for Patients With Colon Cancer | NCT00256334

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | NCT01071564

A Trial In Patients With Advanced Cancer And Leukemia | NCT00878189

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) (GDC-0449) | NCT00957229

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | NCT01576666

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission | NCT00739661

STAT3 Inhibitor for Solid Tumors | NCT00955812

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | NCT01154452

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | NCT00878163

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | NCT01232829

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage | NCT00887159

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies | NCT00761696

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes | NCT00605475

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | NCT01119599

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | NCT01122901

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer | NCT00645333

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | NCT01131234

Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | NCT01563302

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | NCT01068860

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer | NCT01255800

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists | NCT00968981

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | NCT01238133

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | NCT01292655

Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention | NCT00578396

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors | NCT01106508

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | NCT01431794

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | NCT01579929

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy | NCT01141569

Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | NCT01198535

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) | NCT00288704

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | NCT01217411

A Study Of PF-04449913 Administered Alone In Select Solid Tumors | NCT01286467

Rilonacept for Treatment of Familial Mediterranean Fever (FMF) | NCT00582907

LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer | NCT01757327

Rilonacept in Diabetes Mellitus Type 1: Safety Study (RID-A) | NCT00962026

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis | NCT01273389

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis | NCT01532869

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults | NCT00534495

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis | NCT01371617

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | NCT02073838

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer | NCT01151449

Notch Inhibitor in Advanced Cancer | NCT01158404

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | NCT01839604

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients | NCT00581945

IL1-TRAP, Rilonacept, in Systemic Sclerosis | NCT01538719

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma | NCT01310816

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | NCT01653470

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer | NCT01149356

Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer (PITCH) | NCT01637532

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | NCT02129101

Anakinra to Prevent Adverse Post-infarction Remodeling (2) (VCU-ART2) | NCT01175018

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT01193881

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | NCT00927875

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT01145456

Rilonacept to Improve Artery Function in Patients With Atherosclerosis | NCT00417417

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors | NCT01198184

Interleukin-1 Trap to Treat Autoinflammatory Diseases | NCT00094900

Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction | NCT01491074

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | NCT01196416

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | NCT01363817

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | NCT00959647

Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes | NCT00645840

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes (anti IL-1) | NCT00947427

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | NCT01189240

A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies | NCT01204073

Long Term Study of Canakinumab (ACZ885) in Patients With Gout | NCT00927810

Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy | NCT00819585

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT01066663

A Study of LY2940680 in Small Cell Lung Cancer | NCT01722292

RO4929097 in Treating Patients With Metastatic Colorectal Cancer | NCT01116687

PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant | NCT01841333

An East Asian Study of LDE225 | NCT01208831

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis | NCT01981551

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. (β-RELIEVED-II) | NCT01080131

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors | NCT01218620

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis | NCT00487825

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout | NCT00663169

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis | NCT00424346

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure | NCT01300650

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) | NCT00642460

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer | NCT01423903

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | NCT01158274

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | NCT01200810

Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis | NCT01603355

Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma | NCT01358045

A Phase II Study of Itraconazole in Biochemical Relapse | NCT01787331

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients | NCT01356602

Articles citing this

Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J (2017) 0.77

Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat (2016) 0.77

Hepatocellular carcinoma stem cell-like cells are enriched following low-dose 5-fluorouracil chemotherapy. Oncol Lett (2016) 0.77

Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. Mol Clin Oncol (2015) 0.75

Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features. BMC Cancer (2015) 0.75

The Epithelial Sodium Channel and the Processes of Wound Healing. Biomed Res Int (2016) 0.75

The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation. Mediators Inflamm (2016) 0.75

Activation of Inflammatory Responses Correlate With Hedgehog Activation and Precede Expansion of Cancer Stem-Like Cells in an Animal Model of Residual Triple Negative Breast Cancer after Neoadjuvant Chemotherapy. Cancer Stud Mol Med (2015) 0.75

Effect of surgical wound fluids after intraoperative electron radiotherapy on the cancer stem cell phenotype in a panel of human breast cancer cell lines. Oncol Lett (2016) 0.75

Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. Int J Mol Sci (2017) 0.75

Articles cited by this

(truncated to the top 100)

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82

Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17

Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17

Identification of human brain tumour initiating cells. Nature (2004) 38.87

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52

Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44

Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59

Cutaneous wound healing. N Engl J Med (1999) 19.12

Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64

STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45

Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89

Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36

Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06

Regulation of wound healing by growth factors and cytokines. Physiol Rev (2003) 9.82

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66

Identification of cells initiating human melanomas. Nature (2008) 8.28

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98

Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol (2009) 7.95

Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91

Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65

Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell (2011) 7.30

The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell (2009) 6.44

Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell (2011) 6.21

c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53

A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell (2000) 5.53

Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature (2007) 5.19

Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol (2007) 5.16

WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97

Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22

Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci (2007) 4.07

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05

Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci (2003) 3.98

Aberrant activation of notch signaling in human breast cancer. Cancer Res (2006) 3.92

Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer (2002) 3.91

Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87

Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells (2007) 3.60

The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55

Jagged: a mammalian ligand that activates Notch1. Cell (1995) 3.51

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell (2009) 3.48

Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A (2011) 3.42

Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat Cell Biol (2012) 3.30

Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol (2010) 3.22

Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J (1999) 3.19

Nerve-derived sonic hedgehog defines a niche for hair follicle stem cells capable of becoming epidermal stem cells. Cell Stem Cell (2011) 3.19

Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol (2008) 2.98

Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med (2009) 2.95

Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature (2013) 2.85

Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen (2009) 2.83

Epidermal stem cells arise from the hair follicle after wounding. FASEB J (2007) 2.81

Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 2.80

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res (2010) 2.77

Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells (2011) 2.75

Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol (2001) 2.74

Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res (2007) 2.54

Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling. Science (2013) 2.52

Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol (2011) 2.52

The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci (2009) 2.51

Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep (2010) 2.32

Notch signaling in vascular development. Arterioscler Thromb Vasc Biol (2003) 2.31

Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A (2010) 2.22

Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol (2010) 2.20

Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell (2009) 2.19

Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol (1998) 2.17

Notch signaling in cancer. Curr Mol Med (2006) 2.14

Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res (2004) 2.12

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04

Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development (1997) 2.03

Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol (2007) 2.02

Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J (2000) 1.99

Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science (2014) 1.99

Epidermal Notch signalling: differentiation, cancer and adhesion. Curr Opin Cell Biol (2008) 1.99

Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene (2012) 1.95

High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol (2007) 1.94

Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. Circulation (2006) 1.91

Molecular link mechanisms between inflammation and cancer. Curr Pharm Des (2012) 1.88

The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med (2004) 1.86

Radiation-induced reprogramming of breast cancer cells. Stem Cells (2012) 1.83

Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med (2006) 1.82

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol (2010) 1.79

Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A (2004) 1.77

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest (2013) 1.76

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res (2013) 1.76

Notch signaling regulates left-right asymmetry determination by inducing Nodal expression. Genes Dev (2003) 1.76

p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells (2006) 1.72

JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat (2007) 1.69